Showing results (241-250 of 250) with videos related to

Sort By:
Pageof 25
You have reached the last page of results.This site can display upto 250 results.
Nature Medicine|June 21, 2020
Author Correction: Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanomaDavid Liu, Bastian Schilling, Derek Liu, et al.
Nature Medicine|December 4, 2019
Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanomaDavid Liu, Bastian Schilling, Derek Liu, et al.
The New England Journal of Medicine|September 30, 2014
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanomaGeorgina V Long, Daniil Stroyakovskiy, Helen Gogas, et al.
European Journal of Cancer (Oxford, England : 1990)|January 23, 2024
The side effect registry immuno-oncology (SERIO) - A tool for systematic analysis of immunotherapy-induced side effectsCarolin Ertl, Theresa Ruf, Dirk Mentzer, et al.
NEJM Evidence|September 24, 2024
Sequencing of Checkpoint or BRAF/MEK Inhibitors on Brain Metastases in MelanomaPaolo A Ascierto, Mario Mandalà, Pier Francesco Ferrucci, et al.
Nature Communications|January 3, 2024
Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trialPaolo A Ascierto, Milena Casula, Jenny Bulgarelli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 26, 2022
Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)Jeffrey S Weber, Dirk Schadendorf, Michele Del Vecchio, et al.
Journal of Translational Medicine|June 5, 2013
Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012"Paolo A Ascierto, Antonio M Grimaldi, Nicolas Acquavella, et al.
European Journal of Cancer (Oxford, England : 1990)|March 16, 2025
Immune checkpoint inhibition in metastatic or non-resectable melanoma after failure of adjuvant anti-PD-1 treatment. A EUMelaReg real-world evidence studyMichael Weichenthal, Eva Ellebaek, Joanna Mangana, et al.
Nature Genetics|April 29, 2020
Genome-wide association meta-analyses combining multiple risk phenotypes provide insights into the genetic architecture of cutaneous melanoma susceptibilityMaria Teresa Landi, D Timothy Bishop, Stuart MacGregor, et al.
Pageof 25